Marcia Brose, MD, PhD, discusses the rationale, background, and results from the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.
Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose MD, PhD, FASCO iis a professor in the Department of Medical Oncology at Sidney Kimmel Medical College Thomas Jefferson University, in Philadelphia, PA. She is also the vice chair Department of Medical Oncology Jefferson Northeast and the chief of Cancer Services at Sidney Kimmel Cancer Center-Jefferson Northeast and the associate director of Community Based Clinical Research, SKCC chair of Hematology/Oncology at Jefferson Torresdale Hospital.
Articles by Marcia S. Brose, MD, PhD, FASCO